Physician profile
Steven Kent
NPI 1881127587
$8,079.35
in general payments reported to CMS, 2019-2025
31 companies · $2,446 in 2025
The $2,446 reported for 2025 was more than what 91% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $226 · 2021: $123 · 2022: $496 · 2023: $1,975 · 2024: $1,477 · 2025: $2,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,704 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,704.25 |
| Education | $194.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,517.83 | 2019-2025 | |
| Genzyme Corporation | $782.04 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $617.18 | 2019-2025 | Libtayo, Dupixent |
| Dermavant Sciences, INC. | $423.99 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $409.76 | 2019-2025 | |
| Janssen Biotech, INC. | $381.98 | 2019-2025 | Tremfya |
| Celgene Corporation | $374.98 | 2019 | |
| Organogenesis INC. | $353.93 | 2022-2025 | Via Matrix, Nushield, Simplimax |
| Incyte Corporation | $294.06 | 2023-2025 | Opzelura |
| Pfizer INC. | $288.40 | 2019-2025 | |
| Galderma Laboratories, L.P. | $211.51 | 2020-2025 | Nemluvio, Dysport |
| Kerecis Limited | $198.35 | 2023-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Surgiclose |
| Sun Pharmaceutical Industries INC. | $187.54 | 2023-2024 | Ilumya |
| Amgen INC. | $160.46 | 2023-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $147.59 | 2019-2025 | Siliq, Jublia, Cabtreo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $144.29 | 2023-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $124.58 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $109.33 | 2023 | |
| Ucb, INC. | $71.00 | 2023-2025 | Bimzelx, Cimzia |
| Organon LLC | $59.78 | 2025 | Vtama |
| Janssen Pharmaceuticals, INC | $31.22 | 2019-2025 | Tremfya |
| Convatec INC. | $26.19 | 2023 | |
| Verrica Pharmaceuticals INC. | $25.34 | 2024 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $20.62 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.17 | 2024 | |
| Mayne Pharma Commercial LLC | $19.83 | 2024 | |
| Sanara Medtech INC. | $19.02 | 2025 | Celleraterx |
| Prugen, INC. Pharmaceuticals | $17.57 | 2019 | |
| Allergan, INC. | $15.60 | 2019 | |
| Botanix Sb INC | $14.01 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.